Sunshine Biopharma, Inc.
SBFMHealthcare|Drug Manufacturers - Specialty & Generic|US
$2.71
-0.08 (-2.87%)
Tangible Book / Share
$376.41
Cash / Share
$201.39
Financials
Financial Snapshot
Market Cap
$5.8M
Enterprise Value
-$7.3M
Revenue (TTM)
$35.3M
Net Income (TTM)
-$5.8M
Cash & Investments
$13.7M
Net Cash
$13.1M
Free Cash Flow (TTM)
-$4.6M
Operating CF (TTM)
-$5.3M
Debt/Equity
0.02
Cash Runway & Burn Rate
Cash on Hand
$13.7M
Quarterly Burn
$1.3M
Monthly Burn
$444.5K
Est. Runway
~10.3 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $57.5K | $107.5K | $115.2K | $48.1K | $997.5K | $2.0M | $21.8M | $16.3M | $9.7M | $9.1M | $13.7M | |
| Operating Cash Flow | -$314.2K | -$543.5K | -$512.8K | -$495.8K | -$657.3K | -$1.8M | -$5.2M | -$8.8M | -$12.5M | -$5.3M | -$5.3M | |
| Free Cash Flow | -$317.6K | -$547.2K | -$531.7K | -$496.7K | -$658.5K | -$1.8M | -$5.6M | -$9.6M | -$14.9M | -$5.5M | -$4.6M | |
| Capital Expenditure | -$3.4K | -$3.7K | -$18.9K | -$860.00 | -$1.2K | -$2.00 | -$305.0K | -$788.1K | -$2.3M | -$174.5K | $736.1K | |
| Financing Cash Flow | $324.6K | $670.7K | $527.6K | $442.3K | $1.6M | $2.9M | $39.5M | $3.4M | $9.3M | $4.7M | $8.6M |
R&D Spending
R&D (TTM)
-$366.6K
R&D Intensity
-1.0%
R&D Growth vs Prior
-160.7%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $447.2K | $21.1K | $71.4K | $228.4K | $4.3M | $24.1M | $34.9M | $36.3M | $35.3M | |
| R&D Expense | $32.8K | $0.00 | $12.8K | $15.2K | $1.7K | $672.2K | $811.9K | $1.9M | $933.9K | $604.3K | -$366.6K | |
| R&D % of Revenue | — | — | 2.9% | 72.0% | 2.4% | 294.3% | 18.7% | 7.7% | 2.7% | 1.7% | -1.0% | |
| SG&A | $899.6K | $850.6K | $1.2M | $622.7K | $606.6K | $1.9M | $9.5M | $10.8M | $14.9M | $19.6M | $19.2M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $447.2K | $21.1K | $71.4K | $228.4K | $4.3M | $24.1M | $34.9M | $36.3M | $35.3M | |
| Cost of Revenue | $60.7K | $6.6K | $391.1K | $11.1K | $25.8K | $117.8K | $2.6M | $15.8M | $24.2M | $24.4M | $24.8M | |
| Gross Profit | -$60.7K | -$6.6K | $56.1K | $10.1K | $45.6K | $110.6K | $1.7M | $8.3M | $10.7M | $11.9M | $10.5M | |
| R&D | $32.8K | $0.00 | $12.8K | $15.2K | $1.7K | $672.2K | $811.9K | $1.9M | $933.9K | $604.3K | -$366.6K | |
| SG&A | $899.6K | $850.6K | $1.2M | $622.7K | $606.6K | $1.9M | $9.5M | $10.8M | $14.9M | $19.6M | $19.2M | |
| Operating Income | -$993.1K | -$857.2K | -$1.2M | -$641.6K | -$576.9K | -$2.4M | -$8.7M | -$4.8M | -$5.8M | -$4.5M | -$5.2M | |
| Interest Expense | $34.7K | $104.8K | $159.4K | $115.9K | $168.1K | $328.8K | $39.4K | $137.3K | $8.8K | $0.00 | $0.00 | |
| Pretax Income | -$3.5M | -$1.0M | -$2.2M | -$1.1M | -$2.8M | -$12.4M | -$26.5M | -$4.1M | -$5.4M | -$6.0M | -$5.6M | |
| Net Income | -$3.5M | -$1.0M | -$2.2M | -$1.7M | -$2.8M | -$12.4M | -$26.7M | -$4.5M | -$5.1M | -$6.0M | -$5.8M | |
| EPS (Diluted) | -32926.00 | -4768.00 | -28400.00 | -3773388.00 | -642978.00 | -1904000.00 | -704728.00 | -70272.00 | -1464.00 | -288.00 | -203.00 | |
| EBITDA | -$932.4K | -$928.8K | -$2.0M | -$948.4K | -$2.6M | -$12.1M | -$26.4M | -$3.8M | -$5.1M | -$5.6M | -$5.3M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.07 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $57.5K | $107.5K | $115.2K | $40.5K | $989.9K | $2.0M | $21.8M | $16.3M | $9.7M | $9.1M | $13.7M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $7.6K | $7.6K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $58.5K | $117.2K | $211.5K | $65.7K | $1.0M | $2.2M | $27.3M | $24.9M | $26.0M | $26.9M | $30.7M | |
| Total Assets | $64.4K | $257.5K | $1.1M | $98.1K | $1.0M | $2.2M | $29.5M | $27.3M | $30.6M | $30.1M | $33.6M | |
| Total Current Liabilities | $274.1K | $751.1K | $912.5K | $833.5K | $1.1M | $91.2K | $6.9M | $5.6M | $6.3M | $6.4M | $5.6M | |
| Long-Term Debt | $0.00 | $79.7K | $289.8K | $0.00 | $949.0K | $1.9M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $274.1K | $830.8K | $1.2M | $833.5K | $2.0M | $2.0M | $7.9M | $6.1M | $7.1M | $7.0M | $6.1M | |
| Stockholders' Equity | -$209.7K | -$573.4K | -$55.8K | -$735.4K | -$954.8K | $211.7K | $21.6M | $21.2M | $23.5M | $23.0M | $27.5M | |
| Retained Earnings | -$12.6M | -$13.6M | -$15.8M | -$17.4M | -$20.2M | -$32.7M | -$59.4M | -$63.9M | -$69.0M | -$75.0M | -$77.8M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$314.2K | -$543.5K | -$512.8K | -$495.8K | -$657.3K | -$1.8M | -$5.2M | -$8.8M | -$12.5M | -$5.3M | -$5.3M | |
| Capital Expenditure | -$3.4K | -$3.7K | -$18.9K | -$860.00 | -$1.2K | -$2.00 | -$305.0K | -$788.1K | -$2.3M | -$174.5K | $736.1K | |
| Free Cash Flow | -$317.6K | -$547.2K | -$531.7K | -$496.7K | -$658.5K | -$1.8M | -$5.6M | -$9.6M | -$14.9M | -$5.5M | -$4.6M | |
| Investing Cash Flow | -$3.4K | -$84.0K | -$13.9K | -$15.3K | -$1.2K | $0.00 | -$14.6M | -$656.1K | -$2.3M | -$836.3K | -$278.1K | |
| Financing Cash Flow | $324.6K | $670.7K | $527.6K | $442.3K | $1.6M | $2.9M | $39.5M | $3.4M | $9.3M | $4.7M | $8.6M | |
| Issuance of Stock | $104.1K | $63.9K | $0.00 | $0.00 | $0.00 | $0.00 | $43.6M | $4.1M | $12.1M | $4.7M | $8.5M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$99.0K | -$541.1K | -$3.1M | $0.00 | $0.00 | |
| Net Debt Issuance | $198.2K | $570.6K | $471.0K | $416.5K | $1.6M | $2.9M | -$1.9M | -$126.0K | $347.9K | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Change in Cash | $6.7K | $50.1K | $7.7K | -$74.7K | $949.4K | $1.1M | $19.8M | -$5.5M | -$6.6M | -$563.2K | $3.4M |
Dilution Tracker
Shares outstanding grew 519525.0% over 5 years — significant dilution
Shares Outstanding
2M
5-Year Share Growth
+519525.0%
Stock Issuance (TTM)
$8.5M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.07 | |
| Change vs Prior % | — | — | -65.1% | -88.2% | -55.6% | 75.0% | 442.9% | 60.5% | 5652.5% | 492.3% | 228.4% | |
| Stock Issuance | $104.1K | $63.9K | $0.00 | $0.00 | $0.00 | $0.00 | $43.6M | $4.1M | $12.1M | $4.7M | $8.5M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$99.0K | -$541.1K | -$3.1M | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | 12.5% | 47.7% | 63.8% | 48.4% | 39.0% | 34.6% | 30.6% | 32.8% | 29.8% | |
| Operating Margin % | — | — | -260.9% | -3037.9% | -807.8% | -1068.2% | -199.6% | -19.9% | -16.7% | -12.3% | -14.7% | |
| Net Margin % | — | — | -482.1% | -7860.9% | -3898.7% | -5444.4% | -615.4% | -18.7% | -14.7% | -16.5% | -16.5% | |
| EBITDA Margin % | — | — | -444.7% | -4490.2% | -3643.6% | -5294.9% | -608.6% | -15.9% | -14.7% | -15.5% | -14.9% | |
| FCF Margin % | — | — | -118.9% | -2351.5% | -922.1% | -800.8% | -127.8% | -39.7% | -42.6% | -15.2% | -13.0% | |
| ROE % | 1667.5% | 181.4% | 3867.3% | 225.8% | 291.6% | -5875.6% | -123.7% | -21.2% | -21.8% | -25.9% | -24.2% | |
| ROA % | -5429.3% | -404.0% | -188.1% | -1691.7% | -266.3% | -564.6% | -90.5% | -16.5% | -16.8% | -19.9% | -17.3% | |
| ROIC % | -3641.6% | -374.4% | -130.1% | 3237.8% | -60.2% | -115.6% | -38.1% | -21.8% | -22.7% | -18.8% | -18.4% | |
| R&D / Revenue % | — | — | 2.9% | 72.0% | 2.4% | 294.3% | 18.7% | 7.7% | 2.7% | 1.7% | -1.0% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -100.0% | 0.0% | 0.0% | -95.3% | 238.1% | 219.9% | 1802.4% | 454.4% | 44.7% | 4.1% | |
| Gross Profit | -3655.7% | 89.1% | 946.6% | -82.1% | 352.4% | 142.7% | 1434.0% | 391.5% | 27.9% | 11.8% | |
| Operating Income | -27.3% | 13.7% | -36.1% | 45.0% | 10.1% | -323.0% | -255.5% | 44.8% | -21.5% | 22.9% | |
| Net Income | -111.5% | 70.3% | -107.3% | 23.0% | -67.7% | -346.7% | -115.0% | 83.2% | -13.9% | -16.4% | |
| EPS (Diluted) | 100.0% | 85.5% | -495.6% | -13186.6% | 83.0% | -196.1% | 63.0% | 90.0% | 97.9% | 80.3% | |
| Operating Cash Flow | 63.8% | -73.0% | 5.7% | 3.3% | -32.6% | -178.3% | -186.9% | -67.2% | -42.8% | 57.5% | |
| Free Cash Flow | 78.7% | -72.3% | 2.8% | 6.6% | -32.6% | -177.8% | -203.6% | -72.2% | -55.3% | 62.9% | |
| R&D Expense | 278.8% | -100.0% | 0.0% | 18.8% | -88.6% | 38801.0% | 20.8% | 128.6% | -49.7% | -35.3% | |
| SG&A Expense | 17.0% | -5.4% | 42.0% | -48.4% | -2.6% | 207.6% | 408.0% | 14.3% | 37.9% | 31.4% | |
| Total Assets | -90.4% | 299.8% | 345.3% | -91.4% | 965.3% | 110.7% | 1241.2% | -7.4% | 11.8% | -1.6% | |
| Book Value / Share | 100.0% | 0.0% | 72.1% | -11038.3% | -192.1% | 112.7% | 1782.3% | -38.9% | -98.1% | -83.4% | |
| Debt | -79.2% | 238.6% | 18.7% | -24.9% | 167.4% | -0.7% | -59.7% | -14.1% | 44.8% | -14.7% | |
| Diluted Shares | -100.0% | 0.0% | -65.1% | -88.2% | -55.6% | 75.0% | 442.9% | 60.5% | 5652.5% | 492.3% |
Valuation
P/E (TTM)At Loss
P/S0.16
10Y Low / Med / High0.06 / 17.59 / 1087.66
P/B0.01
10Y Low / Med / High0.09 / 0.31 / 38.66
EV/EBITDA1.39
10Y Low / Med / High0.43 / 1.29 / 2.36
EV/Revenue-0.21
10Y Low / Med / High30.52 / 108.66 / 1089.53
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$376.41
Net Current Assets / Share
$11.57
Graham Net-Net
$245.23
Cash / Share
$201.39
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -971.88 | -19966.44 | -225.35 | -0.05 | -0.49 | -0.60 | -0.36 | -1.55 | -0.41 | -0.85 | -0.01 | |
| P/S Ratio | 0.00 | 0.00 | 1087.66 | 76.70 | 17.59 | 35.82 | 2.24 | 0.27 | 0.06 | 0.14 | 0.16 | |
| P/B Ratio | 0.00 | -36196.27 | -8724.19 | -2.20 | -1.32 | 38.66 | 0.45 | 0.31 | 0.09 | 0.22 | 0.01 | |
| EV/EBITDA | -0.19 | -22345.76 | -244.98 | -2.42 | -0.84 | -0.66 | 0.43 | 2.36 | 1.29 | 0.57 | 1.39 | |
| EV/Revenue | 0.00 | 0.00 | 1089.53 | 108.66 | 30.52 | 35.19 | -2.61 | -0.37 | -0.19 | -0.09 | -0.21 |
Analyst Estimates & Quality
Altman Z-Score
-1.28
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 |
|---|---|---|
| Revenue | $35.8M | $45.0M |
| Net Income | -$810.7K | -$166.3K |
| EPS | $-39.00 | $-8.00 |
| # Analysts (EPS) | 1 | 1 |